APVO - アプテボ・セラピュ―ティクス (Aptevo Therapeutics Inc.) アプテボ・セラピュ―ティクス



symbol APVO
会社名 Aptevo Therapeutics Inc (アプテボ・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アプテボ・セラピューティクス(Aptevo Therapeutics Inc.)はバイオ技術会社である。同社は患者の生命を管理するためにオンコロジー(がん)及び血液学(血液疾患)治療薬の生産に従事する。同社の事業はオンコロジー及び血液学治療薬の発見・開発・商品化・販売を行う。核心技術はADAPTIS(モジュラータンパク質技術)プラットフォームである。同社は血液学と感染症分野で約4つの製品を有し、並びに免疫腫瘍学における多様な治験段階の製品候補を有する。その治験段階の製品候補であるMOR209/ES414、ES210、ES425及びotlertuzumabはADAPTISプラットフォーム上に構築される。同社の販売製品は「WinRho SDF」(抗 D(Rho)ヒト免疫グロブリン)、「HepaGam B」(B型肝炎ヒト免疫グロブリン)、「VARIZIG」(水痘帯状疱疹ヒト免疫グロブリン)及び「IXINITY」(血液凝固第IX因子(組換え型))である。   アプテボ・セラピュ―ティクスは米国のバイオ医薬品企業。主にがんと血液疾患に対し、同社開発のモジュラ―・タンパク質技術「ADAPTIR」による治療に従事する。がん治療、免疫療法に利用される候補薬に「MOR209/ES414」、「ES210」、「ES425」、「Otlertuzumab」などを含む。本社はワシントン州シアトル。   Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The Company's lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed based on the Company's versatile and robust ADAPTIR™ modular protein technology platform. The ADAPTIR™ platform is capable of generating highly differentiated bispecific antibodies with unique mechanisms of action for the treatment of different types of cancer.
本社所在地 2401 4th Avenue Suite 1050 Seattle WA 98121 USA
電話番号 +1 206-838-0500
設立年月日 42401
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 121人
url www.AptevoTherapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/apvo
EBITDA EBITDA(百万ドル) -50.97500
終値(lastsale) 4.6
時価総額(marketcap) 104279263
時価総額 時価総額(百万ドル) 102.46570
売上高 売上高(百万ドル) 19.88700
企業価値(EV) 企業価値(EV)(百万ドル) 77.30170
当期純利益 当期純利益(百万ドル) -33.79400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Aptevo Therapeutics Inc revenues increased 92% to $10.9M. Net loss before extraordinary items increased 5% to $27.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing increase of 52% to $17.4M (expense) Other expense from continuing operations increase of 22% to $1.1M (expense).



   Aptevo Therapeutics GAAP EPS of $1.57 beats by $0.64, revenue of $3.11M in-line (NASDAQ:APVO)  2023/03/30 13:10:45 Seeking Alpha
Aptevo Therapeutics press release (APVO): FY GAAP EPS of $1.57 beats by $0.64.Revenue of $3.11M (-74.7% Y/Y) in-line.Aptevo had cash and cash equivalents as of December 31, 2022…
   Aptevo Therapeutics raises $9.6M in non-dilutive funding  2023/03/30 11:47:01 Seeking Alpha
Aptevo Therapeutics (APVO) has raised $9.6M in non-dilutive funding, extending its cash runway beyond 12 months with an additional $50K possible based on IXINITY sales in 1Q 23.The…
   XOMA Acquires Cashflow-Generating Asset for its Royalty and Milestone Portfolio  2023/03/30 11:30:00 GlobeNewswire
Acquired IXINITY® commercial payment and milestone economics from Aptevo Therapeutics Acquired IXINITY® commercial payment and milestone economics from Aptevo Therapeutics
   The Top 7 Growth Stocks in Biotech  2023/03/03 23:57:06 InvestorPlace
Biotech stocks almost always have the potential for significant growth over time. Companies in the sector operate in areas including drug development, medical devices, and diagnostics. The rewards for bringing such products to market are significant. But biotech growth stocks also generally carry much higher risk than the average stock. Additionally, companies in the biotech industry face regulatory approval processes and intellectual property disputes that can result in significant near-term volatility. Nevertheless, the potential for substantial returns makes biotech stocks perpetually attractive. Identifying companies with the best chances of developing breakthrough drugs or therapies is paramount to success. Let’s take a look at seven companies that I think fit that profile. ITOS iTeos Therapeutics $17.30 VIR Vir Biotechnology $22.84 BEAM Beam Therapeutics $39.10 KNSA Kiniksa Pharmaceuticals $12.28 DVAX Dynavax Technologies $10.44 CMRX Chimerix $1.63 APVO Aptevo Therapeutics $2.15 iTeos Therapeutics (ITOS) Source: motorolka / Shutterstock.com Stocks like iTeos Therapeutics (NASDAQ: ITOS ) are the kind of equity biotech investors ought to be looking for.
   Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial  2023/02/13 13:05:00 Accesswire
Trial to Evaluate Safety, Tolerability and Clinical Activity in Solid Tumors Expressing 5T4 LUND, SWEDEN and SEATTLE, WA / ACCESSWIRE / February 13, 2023 / Alligator Bioscience AB ("Alligator") (Nasdaq Stockholm: ATORX) and Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) today announced the dosing of the first patient in the companies'' Phase 1 trial evaluating ALG.APV-527 for the treatment of solid tumors expressing the tumor-associated antigen 5T4. ALG.APV-527 is a bispecific antibody with a tumor-directed 4-1BB agonistic effect and the ability to specifically stimulate antitumor-specific T cells and NK cells involved in tumor control. "We are very pleased to announce the initiation of a clinical trial to evaluate ALG.APV-527 in patients with solid tumors with high prevalence of 5T4. For Aptevo, the initiation of a second clinical program means we are now developing therapeutics to treat both solid tumors and hematological malignancies - a strategic win for our company," said Marvin White, President, and CEO of Aptevo. "ALG.APV-527 is a compelling candidate, as preclinical studies showed it has the potential to activate key immune cell populations within the tumor microenvironment while demonstrating a favorable safety profile.
   Aptevo Therapeutics GAAP EPS of -$1.50 beats by $0.14 (NASDAQ:APVO)  2022/11/10 13:54:18 Seeking Alpha
Aptevo Therapeutics press release (APVO): Q3 GAAP EPS of -$1.50 beats by $0.14.Aptevo had cash, cash equivalents and restricted cash of $22.6 million as of September 30, 2022
   Alligator Bioscience & Aptevo Therapeutics Announce Publication Highlighting ALG.APV-527 Preclinical Data in Peer-Reviewed Journal Molecular Cancer Therapeutics  2022/11/09 13:05:00 Wallstreet:Online
ALG.APV-527 Demonstrates Favorable Preclinical Efficacy and Safety Compared to a First Generation 4-1BB AntibodyALG.APV-527 Rapidly Progressing to Clinical Development for Evaluation in the Treatment of Solid Tumors after Receipt of IND Clearance …
   Aptevo Therapeutics Announces Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition  2022/11/03 13:06:00 Accesswire
Company to Present New Data from On-Going Phase 1b Trial Evaluating Lead Candidate APVO436 for the Treatment of Acute Myeloid Leukemia SEATTLE, WA / ACCESSWIRE / November 3, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced acceptance of a poster presentation at 64th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 10-13 in New Orleans, Louisiana. Details of the presentation, which will be presented live, are as follows: Title: " Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 ADAPTIR™ Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome" Date/Time: Sunday, December 11, 2022, 6:00 PM-8:00 PM Presenter: Justin M. Watts, MD, Associate Professor of Medicine Section Chief, Leukemia, Pap Corps Endowed Professor in Leukemia, Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine About Aptevo Therapeutics Inc.
   Aptevo Therapeutics receives approval to begin human trial of solid tumor therapy  2022/09/19 13:38:15 Seeking Alpha
Alligator Bioscience and Aptevo Therapeutics (APVO) said the U.S
   Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND  2022/09/19 12:45:00 Wallstreet:Online
Drug Candidate progressing to the clinic for evaluation in the treatment of 5T4-expressing tumor antigens in multiple solid tumor typesLUND, SWEDEN and SEATTLE WA / ACCESSWIRE / September 19, 2022 / Alligator Bioscience AB ("Alligator") and Aptevo …
   Aptevo gains after disclosing additional remission data in leukemia trial  2022/06/09 13:35:50 Seeking Alpha
Aptevo Therapeutics (APVO) traded higher in the morning hours Thursday after the clinical-stage biotech announced new remission data on four additional patients enrolled in its Phase…
   Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia  2022/06/09 12:05:00 Wallstreet:Online
Cohort 1 Combination Therapy Arm Shows 36% Remission Rate Among Response-evaluable Patients Treated to DateCohort 3 Monotherapy Patient Achieved Bone Marrow Complete RemissionCompany Also Reports Myelodysplastic Syndrome Patient Enrolled in Dose …
   Aptevo Therapeutics GAAP EPS of -$1.59 misses by $0.66, revenue of $3.11M misses by $0.64M (NASDAQ:APVO)  2022/05/12 12:45:39 Seeking Alpha
Aptevo Therapeutics press release (NASDAQ:APVO): Q1 GAAP EPS of -$1.59 misses by $0.66.Revenue of $3.11M (+28.5% Y/Y) misses by $0.64M.
   Aptevo Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights  2022/05/12 12:05:00 Wallstreet:Online
SEATTLE, WA / ACCESSWIRE / May 12, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and …
   APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual Meeting  2022/04/12 12:05:00 Wallstreet:Online
Preclinical Data Support Potential for APVO442 in Difficult-to-Treat Types of Prostate Cancer, Including Metastatic Castration-Resistant DiseaseSEATTLE, WA / ACCESSWIRE / April 12, 2022 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage …

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アプテボ・セラピュ―ティクス APVO Aptevo Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)